Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study

BACKGROUND: Omalizumab (Xolair®), a recombinant monoclonal anti-IgE antibody, has demonstrated efficacy in clinical trials conducted in patients with moderate to severe persistent allergic asthma. We aimed to investigate the efficacy, discontinuation and medical resource utilization of omalizumab in...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hao-Cheng, Huang, Chien-Da, Chang, Erin, Kuo, Han-Pin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706688/
https://www.ncbi.nlm.nih.gov/pubmed/26747278
http://dx.doi.org/10.1186/s12890-015-0156-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706688/
https://www.ncbi.nlm.nih.gov/pubmed/26747278
http://dx.doi.org/10.1186/s12890-015-0156-2

Ejemplares similares